Eudragit® FS Microparticles Containing Bacteriophages, Prepared by Spray-Drying for Oral Administration

Phage therapy is recognized to be a promising alternative to fight antibiotic-resistant infections. In the quest for oral dosage forms containing bacteriophages, the utilization of colonic-release Eudragit® derivatives has shown potential in shielding bacteriophages from the challenges encountered within the gastrointestinal tract, such as fluctuating pH levels and the presence of digestive enzymes. Consequently, this study aimed to develop targeted oral delivery systems for bacteriophages, specifically focusing on colon delivery and employing Eudragit® FS30D as the excipient. The bacteriophage model used was LUZ19. An optimized formulation was established to not only preserve the activity of LUZ19 during the manufacturing process but also ensure its protection from highly acidic conditions. Flowability assessments were conducted for both capsule filling and tableting processes. Furthermore, the viability of the bacteriophages remained unaffected by the tableting process. Additionally, the release of LUZ19 from the developed system was evaluated using the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model. Finally, stability studies demonstrated that the powder remained stable for at least 6 months when stored at +5 °C.

[1]  B. Schnabl,et al.  Bacteriophages and their potential for treatment of gastrointestinal diseases , 2021, Nature Reviews Gastroenterology & Hepatology.

[2]  H. Chan,et al.  Enteric-coated bacteriophage tablets for oral administration against gastrointestinal infections. , 2021, International journal of pharmaceutics.

[3]  B. Blasdel,et al.  In Vitro Characterization and In Vivo Efficacy Assessment in Galleria mellonella Larvae of Newly Isolated Bacteriophages against Escherichia coli K1 , 2021, Viruses.

[4]  K. Amighi,et al.  A Design of Experiment Approach to Optimize Spray-Dried Powders Containing Pseudomonas aeruginosa Podoviridae and Myoviridae Bacteriophages , 2021, Viruses.

[5]  S. Jafari,et al.  Spray Drying Encapsulation of Bioactive Materials , 2021 .

[6]  Beata Zalewska-Piątek,et al.  Phage Therapy as a Novel Strategy in the Treatment of Urinary Tract Infections Caused by E. Coli , 2020, Antibiotics.

[7]  Jian Li,et al.  Inhalable bacteriophage powders: Glass transition temperature and bioactivity stabilization , 2020, Bioengineering & translational medicine.

[8]  J. Azeredo,et al.  Phage therapy efficacy: a review of the last 10 years of preclinical studies , 2020, Critical reviews in microbiology.

[9]  B. Evrard,et al.  Influence of Composition and Spray-Drying Process Parameters on Carrier-Free DPI Properties and Behaviors in the Lung: A review , 2020, Pharmaceutics.

[10]  I. Gitlin,et al.  The use of hydrophobic amino acids in protecting spray dried trehalose formulations against moisture-induced changes. , 2019, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  S. Abedon,et al.  Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies , 2019, Microbiology and Molecular Biology Reviews.

[12]  M. Vaneechoutte,et al.  Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2) , 2019, Scientific Reports.

[13]  D. Malik,et al.  Microencapsulation of Salmonella-Specific Bacteriophage Felix O1 Using Spray-Drying in a pH-Responsive Formulation and Direct Compression Tableting of Powders into a Solid Oral Dosage Form , 2019, Pharmaceuticals.

[14]  B. Weber-Dąbrowska,et al.  Encapsulation of bacteriophage T4 in mannitol-alginate dry macrospheres and survival in simulated gastrointestinal conditions , 2019, LWT.

[15]  D. Malik,et al.  High precision microfluidic microencapsulation of bacteriophages for enteric delivery. , 2018, Research in microbiology.

[16]  Roberto Bastías,et al.  Encapsulation of specific Salmonella Enteritidis phage f3αSE on alginate-spheres as a method for protection and dosification , 2018 .

[17]  B. Martínez,et al.  Strategies to Encapsulate the Staphylococcus aureus Bacteriophage phiIPLA-RODI , 2018, Viruses.

[18]  W. Britton,et al.  Microfluidic‐assisted bacteriophage encapsulation into liposomes , 2018, International journal of pharmaceutics.

[19]  I. Huys,et al.  The Magistral Phage , 2018, Viruses.

[20]  P. García,et al.  Are Phage Lytic Proteins the Secret Weapon To Kill Staphylococcus aureus? , 2018, mBio.

[21]  J. Li,et al.  Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  G. Vladisavljević,et al.  Microencapsulation of Clostridium difficile specific bacteriophages using microfluidic glass capillary devices for colon delivery using pH triggered release , 2017, PloS one.

[23]  J. Fothergill,et al.  The contribution of Pseudomonas aeruginosa virulence factors and host factors in the establishment of urinary tract infections. , 2017, FEMS microbiology letters.

[24]  P. Dell'orco,et al.  The amorphous state: first-principles derivation of the Gordon-Taylor equation for direct prediction of the glass transition temperature of mixtures; estimation of the crossover temperature of fragile glass formers; physical basis of the "Rule of 2/3". , 2017, Physical chemistry chemical physics : PCCP.

[25]  Anna Kirpichnikova,et al.  Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. , 2017, Advances in colloid and interface science.

[26]  W. Britton,et al.  Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders. , 2017, International journal of pharmaceutics.

[27]  L. Debarbieux,et al.  [Phage therapy: a realistic weapon against multidrug resistant bacteria]. , 2017, Medecine sciences : M/S.

[28]  A. Górski,et al.  Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80 , 2017, Front. Microbiol..

[29]  H. Neve,et al.  Carrier systems for bacteriophages to supplement food systems: Encapsulation and controlled release to modulate the human gut microbiota , 2016 .

[30]  W. Britton,et al.  Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections , 2016, Pharmaceutical Research.

[31]  A. Jo,et al.  Application of chitosan–alginate microspheres for the sustained release of bacteriophage in simulated gastrointestinal conditions , 2015 .

[32]  R. Lavigne,et al.  Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix. , 2014, International journal of pharmaceutics.

[33]  C. Chiu,et al.  Shanghai fever: a distinct Pseudomonas aeruginosa enteric disease , 2013, Gut.

[34]  J. Klumpp,et al.  Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[35]  Qi Wang,et al.  Whey protein improves survival and release characteristics of bacteriophage Felix O1 encapsulated in alginate microspheres , 2013 .

[36]  G. Islan,et al.  Novel biopolymer matrices for microencapsulation of phages: enhanced protection against acidity and protease activity. , 2012, Macromolecular bioscience.

[37]  M. D'souza,et al.  Spray-dried microparticles: a potential vehicle for oral delivery of vaccines , 2012, Journal of microencapsulation.

[38]  Qi Wang,et al.  Enhanced alginate microspheres as means of oral delivery of bacteriophage for reducing Staphylococcus aureus intestinal carriage , 2012 .

[39]  S. Minagawa,et al.  Translocation of Pseudomonas aeruginosa from the Intestinal Tract Is Mediated by the Binding of ExoS to an Na,K-ATPase Regulator, FXYD3 , 2010, Infection and Immunity.

[40]  K. Stanford,et al.  Oral delivery systems for encapsulated bacteriophages targeted at Escherichia coli O157:H7 in feedlot cattle. , 2010, Journal of food protection.

[41]  Alan Brouder,et al.  Handbook of transnational economic governance regimes , 2009 .

[42]  C. F. van der Walle,et al.  A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[43]  Qi Wang,et al.  Microencapsulation of Bacteriophage Felix O1 into Chitosan-Alginate Microspheres for Oral Delivery , 2008, Applied and Environmental Microbiology.

[44]  M. Griffiths,et al.  Bovine whey proteins inhibit the interaction of Staphylococcus aureus and bacteriophage K , 2006, Journal of applied microbiology.

[45]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[46]  P. Bossuyt,et al.  Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial , 2003, The Lancet.

[47]  G. Capellier,et al.  Endemicity, molecular diversity and colonisation routes of Pseudomonas aeruginosa in intensive care units , 2001, Intensive Care Medicine.

[48]  J. Marshall,et al.  The Gastrointestinal Tract The “Undrained Abscess” of Multiple Organ Failure , 1993, Annals of surgery.

[49]  B. Rowlands,et al.  Selective decontamination of the digestive tract: a stratified, randomized, prospective study in a mixed intensive care unit. , 1991, Surgery.

[50]  G. Ramsay,et al.  TRIPLE REGIMEN OF SELECTIVE DECONTAMINATION OF THE DIGESTIVE TRACT, SYSTEMIC CEFOTAXIME, AND MICROBIOLOGICAL SURVEILLANCE FOR PREVENTION OF ACQUIRED INFECTION IN INTENSIVE CARE , 1988, The Lancet.

[51]  D. Malik.  Targeted Delivery of Bacteriophages to the Gastrointestinal Tract and Their Controlled Release , 2019, Microbiome and Metabolome in Diagnosis, Therapy, and other Strategic Applications.

[52]  Jérôme Mantanus,et al.  Design space approach in the optimization of the spray-drying process. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[53]  S. Kshirsagar,et al.  In vitro In vivo comparison of two pH sensitive Eudragit polymers for colon specific drug delivery , 2009 .

[54]  E. Kutter.  Phage host range and efficiency of plating. , 2009, Methods in molecular biology.

[55]  J. Abraham.  The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[56]  Ich Harmonised,et al.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .

[57]  L. Nicolle,et al.  Complicated urinary tract infection in adults. , 2005, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[58]  D. Zandstra,et al.  The effect of selective decontamination of the digestive tract on colonisation and infection rate in multiple trauma patients , 2004, Intensive Care Medicine.